Compare TAYD & TLSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TAYD | TLSA |
|---|---|---|
| Founded | 1955 | 2013 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 170.7M | 155.3M |
| IPO Year | 1995 | 2017 |
| Metric | TAYD | TLSA |
|---|---|---|
| Price | $53.60 | $0.93 |
| Analyst Decision | Hold | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $70.00 | N/A |
| AVG Volume (30 Days) | 47.3K | ★ 256.6K |
| Earning Date | 03-31-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 11.24 | N/A |
| EPS | ★ 2.87 | N/A |
| Revenue | ★ $46,292,725.00 | N/A |
| Revenue This Year | $0.25 | N/A |
| Revenue Next Year | $19.78 | N/A |
| P/E Ratio | $18.63 | ★ N/A |
| Revenue Growth | ★ 3.84 | N/A |
| 52 Week Low | $40.50 | $0.91 |
| 52 Week High | $90.37 | $2.60 |
| Indicator | TAYD | TLSA |
|---|---|---|
| Relative Strength Index (RSI) | 43.01 | 33.91 |
| Support Level | $53.46 | N/A |
| Resistance Level | $61.21 | $1.48 |
| Average True Range (ATR) | 2.53 | 0.12 |
| MACD | -0.39 | -0.03 |
| Stochastic Oscillator | 11.66 | 5.17 |
Taylor Devices Inc is involved in the design, development, manufacture, and marketing of shock absorption, rate control, and energy storage devices for use in various types of machinery, equipment, and structures. The company's product line includes Seismic dampers, Fluidicshoks, Crane and industrial buffers, Self-adjusting shock absorbers, Liquid die springs, and Vibration Dampers. Its products are generally used to absorb, control, or mitigate the motion of masses caused by earthquakes or explosions. The company markets its products to various industries such as industrial, steel mills, buildings, bridges, aerospace, defense, and automotive industries.
Tiziana Life Sciences Ltd is a clinical-stage biotechnology company that specializes in developing transformative therapies for neurodegenerative and neuroinflammatory diseases. The company's clinical pipeline includes drug assets for Non-Active Secondary Progressive Multiple Sclerosis, Multiple System Atrophy, Alzheimer's, and Amyotrophic Lateral Sclerosis. The company's mission is to design and deliver next-generation immunotherapies for neurodegenerative and neuroinflammatory diseases. The company's main immunotherapeutic candidate, Foralumab (TZLS-401), is being developed for Non-Active Secondary Progressive Multiple Sclerosis, Alzheimer's, and other CNS indications.